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883-6 Acute Myocardial infarction Study of Adenosine 
(AMISTAD II) 
Allan Ross, Ray Gibbons, Robed A, Kloner, Victor J. Marder, Gragg W. Stone, R Wayne 
Alexander, George Washington University Medical Center, Washington, DisL of 
Columbia, Emory University School of Medicine, Atlanta, Georgia. 
Background: A previous study of adenosine infusion in the treatment of acute myocardie~ 
infarction (AMISTAD I) suggested clinical efficacy. The potential role of adenosine as an 
effective therapeutic agent in the treatment of MI has remained in question. To approach 
this problem, a randomized, double blind, placebo controlled, multicenter trial (AMISTAD 
II) was performed. 
Methods: The study involved 248 clinical sites in 13 countries (2,118 patients random- 
ized) participating in the main trial, with 62 sites in 4 countries (263 patients) participating 
in a substudy utilizing Tc-99m sestamibi single photon emission computed tomography 
(SPECT) imaging at 120 to 216 hours post randomization for assessment of final infarct 
size. 
Eligible patients with evolving anterolateral myocardial infarction were randomized to 
treatment with a 3 hour infusion of adenosine of 60 mcg/kg/min, 70 mcg/kg/min, or pla- 
cebo. Patients received study medication within +15 minutes of initiation of thrombolytic 
therapy or within 15 minutes prior to pdmary percutaneous mechanical reperfusion. 
Patients were followed untU hospital discharge and throughout a 6 month period after 
randomization for assessment of primary and secondary endpoints, clinical events, and 
safety. 
The primary efficacy endpoint was time from randomization to the first occurrence of con- 
gestive heart failure (CHF) in-hospital (>24 hours post randomization), or the first rehos- 
pitalization for CHF during follow-up, or death from any cause. The secondary efficacy 
endpoints were all cause mortality, cardiovascular mortality, and myocardial infarct size 
measured by SPECT imaging, Safety endpoints were assessed by following adverse 
events occurring during the first 48 hours following randomization, and changes in blood 
pressure and heart rate during the study drug infusion. Clinical events reported include 
all cause hospitalization, reinfarction, stroke, and revascularization (thrombolysis, perou- 
taneous mechanical reperfusion, or coronary artery bypass graft surgery (CABG)). 
Results: The enrollment and follow-up have been completed for all patients. Results will 
be available in fourth quarter 2001 and will be discussed. 
886-2 Excessive Tumour Necrosis Factor Activation Post- 
Infarction Contributes to the Early Susceptibility to 
Myocardial Rupture: Evidence From TNF-/- Transgenic 
Knockout Models 
Mei Sun, Fayez Dawood, Wen-Hu Wen, Josef Panninger, Peter Liu, Heart & Stroke/ 
Richard Lewar Centre of Excellence, U of Toronto, Toronto, Ontario, Canada, Toronto 
Genera/Hospital UHN, Toronto, Ontario, Canada. 
BACKGROUND: We have previously demonstrated that tumour necrosis factor (TNF) is 
expressed in high levels in the post-infarction (MI) myocardium, and may orchestrate 
inflammation and matrix repair. However, excessive TNF activation may contribute to 
early myocardial rupture. 
METHODS: To examine the role of TNF levels in matrix healing post MI, we generated 
MI in C57/BL wild type mice that are rupture prone, and compared them to TNF-/- 
homozygous knockout animals in the same background. The animals were randomized 
to LAD ligation or sham operation, and the mortality, ventricolar morphology, inflamma- 
tory cell infiltrate and local collagen formation were compared. 
RESULTS: The wild type C57BL mice had higher of mortality post MI at 21 days (67% in 
TNF+/+ and 43% in TNF-/-, p<0.05), with the early deaths between days 3-7 were mainly 
attributed to myocardial rupture. Pathology revealed extensive inflammatory cell infiltrate 
and poor collagen formation in the wild type animals, associated with very high levels of 
local TNF production. Knockout TNF-/- littermates in contrast had lower incidence of rup- 
ture, and more attenuated inflammatory infiltrate, but more late ventricular dilatation in 
the survivors. Apoptosis detected by TUNEL and DNA ligase techniques showed exten- 
sive signals in the infarct, border as well as normal remote zone in wild type animals, but 
significantly attenuated in the TNF-/- models. MMP9 activation, associated with wound 
repair, was extensive in the TNF-/- mice, but was confined only to the central infarct zone 
in the wild type animals prone to rupture. 
CONCLUSIONS: We conclude that host predisposition towards high TNF production in 
the post MI myocardium lends susceptibility to infarct rupture. The ability to decrease 
excessive TNF production leads to improved scar formation, less myocardial rupture and 
lower modality, and may represent an interesting approach in high risk rupture prone sit- 
uations post-myocardial infarction. 
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886-1 Patients With Coronary Artery Disease Treated With 
Statina Have Decreased Heat Production From Culprit 
Lesions 
Christodoulos Stafanadis. Konstantinos Toutouzas, Eleftherios Tsiamis, Menolis 
Vavouranakis, Ioannis Kallikazaros, Sophia Vaina, Christina Chrysochoou, Dimos 
Panagiotakos, Christos Pitsevos, Pavlos Toutouzas, Hippokration Hospital, Athens, 
Greece. 
Background: It has been previously shown, that a local inflammatory process is 
involved in atherosclerotic plaques, resulting in increased heat production of the culpdt 
lesions. Also, it has been shown that statins may play an important role in plaque stabili- 
zaflon, due to an additional anti-inflammatory effect. The purpose of the present study 
was to evaluate the effect of statins on atherosclerotic plaque stabilization by measuring 
the temperature of atherosclerotic plaques. Methods: The study population included 86 
patients (pts), 26 pts with stable angina (SA), 36 pts with unstable angina (UA), and 24 
pts with acute myocardial infarction (AMI). All pts underwent diagnostic catheterization. 
Under stalin treatment were 46 pts (14 pts with SA, 18 pts with UA and 14 pts with AMI) 
for a period of over a month, and 40 pts were not receiving statins (12 pts with SA, 18 pts 
with UA and 10 pts with AMI). Aspirin was administered in 65 pts. Total cholesterol and 
low-density cholesterol were measured in all pts. During the diagnostic catheterization, 
we measured the temperature difference (TD) between the atherosclerotic plaque and 
the healthy vessel wall with a thermography catheter previously validated (Medispes 
S.W.A.G.zug-Switzerlend). Results: TD was progressively increased form pts with SA to 
UA and AMI (0.32 ± 0.1 vs 0.41 ± 0.28 vs 0.68 ± 0.41°C, p < 0.02). When we categorized 
the study population into pts receiving statins and pts not treated with statins, TD was 
lower in the treated group (0.30 ± 0.31 vs 0.57 ± 0.40°C, p < 0.01). Moreover, treated pts 
within each clinical syndrome had lower TD compared to untreated pts (SA: 0.23 ± 0.16 
vs. 0.42 ± 0.24°C, p < 0.02, UA: 0.29 ± 0.25 vs. 0.45 ± 0.26°C, p < 0.02 and AMI: 0.56 ± 
0.34 vs. 0.62 ± 0.51°C, p < 0.01). Multivariate analysis showed that treatment with statins 
was an independent factor in the assessment of temperature variation, adjusted for age, 
hypercholesterolemia, hypertension, smoking, aspirin intake, and clinical syndrome. 
Conclusions: Treatment with statins results in less heat production from the culprit 
lesion, indicating stabilization of the culprit atherosclerotic plaque. 
886-3 Sphingosine Contributes to Tumor Necrosis Factor-a- 
Mediated Contractile Dysfunction in Response to 
Coronary Mlcroembollzation 
Matthias Thielmann. Claus Martin, Hilmar Ddrge, Sergej Belosjorow, Uwe Schwanke, 
Arne KrOger, Anita van de Sand, Ina Konietzka, Rainer Schulz, Gerd Heusch, 
Department of Pathophysio/ogy, University of Essen, Essen, Germany. 
Backround: Coronary microembolization results in patchy microinfarction, leukocyte 
infiltration, and increased myocardial tumor necrosis factor-c~ (TNF-(~) levels and finally 
progressive myocardial contractile dysfunction. The negative inotropic effects of TNF-c~ 
in vitro are in part mediated by sphingosine. We therefore examined the effect of the 
ceramidase inhibitor N-oleoylethanolamine (NOE) on myocardial TNF-(~ content (WEHI 
cytolytic bell assay), sphingosine content (HPLC) and contractile function (sonomicrome- 
try) after coronary microembolization in vivo. 
Methods: In enflurane-anesthetized ogs, coronary microembolization was induced by 
infusion of 3,000 microspheres (42 ~m diameter) per ml/min of inflow into the left circum- 
flex coronary artery. Eleven dogs served as controls, whereas six dogs received NOE (74 
p.g/kg IV over 15 min before coronary microembolization, followed by 2.4 I~g/kg/min for 8 
hours). 
Results: In both, controls and dogs receiving NOE, TNF-(x content was increased in the 
microembolized postedor wall (controls: 2039 ± 1122 (mean+ SD), NOE: 1510 ± 457 U/g 
wet weight) over that in the anterior wall (controls: 1070 ± 543, NOE: 973 ± 435 U/g wet 
weight). The sphingosine content was increased in the posterior wall in controls (406 ± 
147 posterior VS. 244 ± 67 pmol/g wet weight anterior wall). While NOE did not change 
the sphingosine content in the anterior wail it completely prevented the increase in the 
postedor wall (241 ± 61 posterior vs. 200 ± 52 pmol/g wet weight antedor wall). Systemic 
hemodynamics and anterior systolic wall thickening remained unchanged for 8 hours 
after microembolization. Posterior systolic wall thickening in controls decreased progres- 
sively (20.6 ± 4.9 % at baseline to 4.1 ± 3.7 % at 8 hours after microembolization). In 
contrast, NOE prevented such decrease in contractile function (19.5 ± 5.7 % at baseline 
vs. 16.4 ± 6.3 % at 8 hours after coronary microembolization). 
Conclusion: Sphingosine acts downstream of TNF-~ and is causally involved in the cor- 
onary microembolizeflon-induced progressive contractile dysfunction. 
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886-4 Ant ibod ies  to Human Heat Shock Protein 60 Pred ic t  
Risk of  Myocard ia l  In farct ion  or  Death In Women 
Jianhui ZhIJ, Joseph B. Muhtsstein, Javier F'. Nieto, Amy Wasserman, Benjamin D. 
Home, Jeffrey L. Anderson, Stephen E. Epstein, Washington Hospital Center, 
Washington, Dist. of Columbia, LDS Hospital Salt Lake Ci~ Utah. 
Background: We previously demonstrated that antibodies to human heat shock protein 
(HSP) 60 are associated with both the presence and severity of coronary artery disease 
(CAD). In the present prospective study, we examined the relation of human HsP60 anti- 
bodies to risk of myocardial infarction (MI) or death among patients with significant CAD 
by angiography. Methods: Blood samples from 880 patients (77% men, mean age 65 
years)were tested for HSP60 IgG antibodies (ELISA). Mean follow-up was 3 years. 
